The U.S. market exclusivity for Trulicity (dulaglutide) is set to expire around 2027 [1][2][3]. This timing is based on the expiration of its listed patents and exclusivities, according to DrugPatentWatch.com [1].
When is Trulicity's Market Exclusivity Actually Over?
While patent expirations are a key factor, the actual end of Trulicity's market exclusivity in the United States is anticipated to be in 2027 [1][2][3]. This date is derived from the information available regarding its primary patents and regulatory exclusivities [1].
What Happens When Trulicity's Patent Expires?
Upon the expiration of Trulicity's patent and exclusivity, generic versions of the drug can enter the market [1]. This typically leads to increased competition and potentially lower prices for patients [1].
Can Biosimilars for Trulicity Be Developed?
Trulicity is a biologic drug, meaning that "biosimilars" rather than "generics" would be developed [4]. Biosimilars are highly similar to the original biologic drug, with no clinically meaningful differences in terms of safety, purity, and efficacy [4]. The development and approval process for biosimilars is distinct from that of small-molecule generics.
Who Makes Trulicity and Are There Competitors?
Trulicity is manufactured by Eli Lilly and Company [5]. The drug is used for the treatment of type 2 diabetes and competes with other GLP-1 receptor agonists and diabetes medications [5]. Other prominent drugs in this class include semaglutide (Ozempic, Rybelsus, Wegovy) and liraglutide (Victoza, Saxenda) [5].
What Are the Likely Next Steps After Patent Expiry?
Following the expiration of Trulicity's exclusivity, companies that have developed biosimilars will likely seek to launch their products [1]. This would introduce competition, potentially impacting Trulicity's market share and pricing [1].
What Clinical Data Supports Trulicity?
Trulicity's efficacy and safety have been established through various clinical trials, demonstrating its role in glycemic control and cardiovascular risk reduction in patients with type 2 diabetes [5]. These trials are the basis for its approval and are reviewed when considering biosimilar applications [4].
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Trulicity Patent Expiry. https://drugpatentwatch.com/
[2] U.S. Food & Drug Administration. (n.d.). Orange Book. https://www.fda.gov/drugs/patent-certification-and-the-or-book/orange-book-bx-patent-and-exclusivity-information-approved-drugs
[3] Eli Lilly and Company. (n.d.). SEC Filings. https://investor.lilly.com/sec-filings/all-sec-filings
[4] U.S. Food & Drug Administration. (n.d.). Biosimilarity. https://www.fda.gov/drugs/biosimilars/biosimilarity
[5] Trulicity (dulaglutide) Prescribing Information. (n.d.). Eli Lilly and Company.